Xtant Medical's Rocky Road to Growth: What's Behind the Slow Start? Xtant Medical Holdings, Inc. 's latest earnings call painted a picture of a company struggling to find its footing in a rapidly changing market.
The divestiture of non core assets and cessation of certain license revenue due to reimbursement changes have taken their toll on reported revenue, leaving analysts and investors wondering if the company's growth trajectory is on track.
The integration of 17 new sales representatives from the Dilon distribution agreement has been a significant challenge for management, consuming valuable resources and contributing to softer than expected Q2 sales performance.